Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 4/20 | 1.00 |
| ▸ | F2 | P00734 | 1/20 | 1.00 |
| ▸ | PLG | P00747 | 1/20 | 1.00 |
| ▸ | KLKB1 | P03952 | 1/20 | 1.00 |
| ▸ | PRSS1 | P07477 | 1/20 | 1.00 |
| ▸ | NPC1 | O15118 | 11/20 | 0.79 |
| ▸ | RAB9A | P51151 | 11/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.79 |
| ▸ | MEN1 | O00255 | 5/20 | 0.79 |
| ▸ | ESR1 | P03372 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.54 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | CASP3 | P42574 | 2/20 | 0.52 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.52 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7335211 | 0.85 | PLAU (0.74) | PLAUF2PLGKLKB1PRSS1 | |
| SCHEMBL1344198 | 0.84 | F2 (0.72) | PLAUF2PLGKLKB1PRSS1 | |
| SCHEMBL7343218 | 0.84 | PLAU (0.72) | PLAUF2PLGKLKB1PRSS1 | |
| SCHEMBL2173418 | 0.83 | HTT (0.71) | PLAUF2PLGKLKB1PRSS1 | |
| SCHEMBL2229842 | 0.82 | NPC1 (0.76) | PLAUF2PLGKLKB1PRSS1 | |
| SCHEMBL3190254 | 0.78 | MEN1 (0.68) | PLAUF2PLGKLKB1PRSS1 | |
| SCHEMBL3503370 | 0.77 | NPC1 (0.84) | PLAUF2PLGKLKB1PRSS1 | |
| SCHEMBL7334109 | 0.77 | PLAU (0.63) | PLAUF2PLGKLKB1PRSS1 | |
| SCHEMBL1247713 | 0.77 | NPC1 (0.71) | PLAUF2PLGKLKB1PRSS1 | |
| SCHEMBL11847165 | 0.77 | F2 (0.62) | PLAUF2PLGKLKB1PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7217794-B2 | Compounds and methods for treatment of thrombosis | DAIAMED, INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-20050143317-A1 | Compounds and methods for treatment of thrombosis | EXITHERA PHARMACEUTICALS LLC | 2005-06-30 | — | — | US | disclosed |
| WO-2004103270-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF THROMBOSIS | SUNTORY PHARMACEUTICAL RESEARCH LABORATORIES LLC (US) | 2004-12-02 | — | — | WO | disclosed |
| WO-2004089297-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF THROMBOSIS | SUNTORY PHARMACEUTICAL RESEARCH LABORATORIES, LLC (US) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143317-A1 | Compounds and methods for treatment of thrombosis | SERPINC1, F11, F13B | PLAU 28/4885F2 5/4885PLG 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.